Champions Oncology (CSBR)
Provides oncology research services, patient-derived models, testing platforms, and data offerings for biopharma.
Something off on this page? Send us feedback.
Provides preclinical and clinical oncology R&D services to biopharma organizations, using patient-derived cancer models and proprietary testing platforms. Revenue includes pharmacology services and TOS data licensing.
Preclinical and clinical oncology R&D services for biopharma organizations draw on an annotated bank of patient-derived xenograft and primary hematological-malignancy models. Proprietary in-vivo and ex-vivo platforms and bioanalytical capabilities support programs from drug discovery through development. These capabilities generate data for oncology programs.
Pharmacology services sit alongside Translational Oncology Solutions data licensing and other data-and-analytics work. The company describes its services as global, while its executive office is in Hackensack, New Jersey. Its operating model depends on the model bank, proprietary testing platforms, and data offerings supporting oncology drug-development programs.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Sep 12, 2024 | Craig-Hallum | Upgrade | Hold | Buy |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Apr 30, 2026Cash & short-term investments $4.9M · Total debt $4.6M · Total assets $27.0M · Shareholders' equity $3.9M
- Revenue
- $13.8M
- Operating income
- −$631.0K
- Net income
- −$729.0K
No dividends on record.
| Institutions25 holders · as of Mar 31, 2026 | 41.26% | 5.73M shares | |
| Insiders2 holders · as of Nov 6, 2025 | 7.65% | 1.06M shares | |
| Otherremainder | 51.09% | 7.10M shares |
13.89M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Battery Management Corp.Institution | 17.43% | 2.42M | 13Fas of Mar 31, 2026 |
Nea Management Company, LLCInstitution | 12.33% | 1.71M | 13Fas of Mar 31, 2026 |
Joel AckermanInsiderdirector | 7.60% | 1.06M | Form 4filed Nov 6, 2025 ↗ |
Tocqueville Asset Management L.P.Institution | 2.30% | 319,674 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 2.16% | 299,520 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Charles River Laboratories
PDX-based oncology CRO and drug-discovery services
- Evotec (ADR)
Oncology discovery and preclinical development services
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Champions Oncology | $5.15 | +3.00% | $71.6M | — | 51.5 | 1.2 | +12.0% |
| Charles River Laboratories | $291.76 | +0.05% | $14.05B | — | 23.7 | 3.5 | −2.7% |
| Evotec (ADR) | $1.92 | +0.52% | $675.0M | — | — | 0.8 | −17.3% |
| Median | — | 23.7 | 2.2 | −10.0% |